Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Total revenues	$ 36,769	$ 18,385	$ 80,253	$ 48,023
Cost of product revenue	6,867	3,642	15,403	7,882
Research and development	15,165	12,010	39,562	33,830
Selling, general and administrative	13,407	8,797	37,600	26,307
Total costs and operating expenses	35,439	24,449	92,565	68,019
Income (loss) from operations	1,330	(6,064)	(12,312)	(19,996)
Unallocated depreciation and amortization	(768)	(503)	(2,143)	(1,403)
Stock-based compensation	3,016	1,984	8,547	6,092
Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	32,584	13,005	68,397	31,385
Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	4,185	5,380	11,856	16,638
Product revenue
Segment Reporting Information [Line Items]
Total revenues	28,731	8,401	53,674	18,005
Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	28,731	8,401	53,674	18,005
Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	8,038	9,984	26,579	30,018
Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	3,853	4,604	14,723	13,380
Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	4,185	5,380	11,856	16,638
Operating segments
Segment Reporting Information [Line Items]
Total revenues	36,769	18,385	80,253	48,023
Cost of product revenue	6,867	3,642	15,403	7,882
Research and development	14,520	11,617	37,821	32,725
Selling, general and administrative	4,137	3,190	11,346	9,123
Total costs and operating expenses	25,524	18,449	64,570	49,730
Income (loss) from operations	11,245	(64)	15,683	(1,707)
Stock-based compensation	3,016	1,984	8,547	6,092
Operating segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	32,584	13,005	68,397	31,385
Cost of product revenue	6,867	3,642	15,403	7,882
Research and development	5,670	5,184	17,172	15,877
Selling, general and administrative	3,306	2,675	9,294	7,395
Total costs and operating expenses	15,843	11,501	41,869	31,154
Income (loss) from operations	16,741	1,504	26,528	231
Stock-based compensation	1,228	839	3,337	2,335
Operating segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	4,185	5,380	11,856	16,638
Cost of product revenue	0	0	0	0
Research and development	8,850	6,433	20,649	16,848
Selling, general and administrative	831	515	2,052	1,728
Total costs and operating expenses	9,681	6,948	22,701	18,576
Income (loss) from operations	(5,496)	(1,568)	(10,845)	(1,938)
Stock-based compensation	272	132	767	625
Operating segments | Product revenue
Segment Reporting Information [Line Items]
Total revenues	28,731	8,401	53,674	18,005
Operating segments | Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	28,731	8,401
Operating segments | Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0
Operating segments | Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	8,038	9,984	26,579	30,018
Operating segments | Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	3,853	4,604
Operating segments | Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	4,185	5,380
Corporate, non-segment
Segment Reporting Information [Line Items]
Total costs and operating expenses	(8,097)	(5,483)	(24,431)	(16,526)
Unallocated depreciation and amortization	(794)	(528)	(2,220)	(1,526)
Income (loss) before income taxes	2,354	(6,075)	(10,968)	(19,759)
Stock-based compensation	$ 1,516	$ 1,013	$ 4,443	$ 3,132